Comparison
Matrixyl vs. TB-500
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Cosmetic
Healing
CAS no.
214047-00-4
no data
Molecular weight
802.06 g/mol
888 g/mol
Half-life
no data
no data
Sequence
Palmitoyl-Lys-Thr-Thr-Lys-SerAc-LKKTETQMechanism of action
Matrixyl
KTTKS is a fragment of the procollagen I sequence and appears to be part of a feedback mechanism in fibroblasts: elevated concentrations signal intact collagen synthesis and downregulate new synthesis, while low concentrations stimulate it. In cell-culture studies, stimulation of collagen types I/III, elastin, fibronectin and glycosaminoglycans has been documented. The palmitoyl modification is intended to improve skin penetration; effect at the site of action (dermal fibroblasts) depends on permeation.
TB-500
Synthetic fragment of the endogenous protein Thymosin Beta-4. In preclinical models, an influence on cell migration, actin sequestration and neovascularisation has been described. Robust human pharmacokinetic data are not publicly available.
Evidence base
Highest evidence
Human RCT
Animal model
Studies
5
3
of which in humans
2
0
Effects recorded
3
4
Open conflicts
0
1
Documented adverse events
1
2